)
Kiniksa Pharmaceuticals International (KNSA) investor relations material
Kiniksa Pharmaceuticals International Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.ARCALYST commercial performance
Growth is driven mainly by new patient enrollments; compliance, patient satisfaction and payer approval remain strong, with average treatment duration at ~3 years.
~450 physicians prescribed ARCALYST for the first time in the latest quarter; ~30% of the prescribing pool have treated two or more patients, and just over 50% of quarterly enrollments come from repeat prescribers.
5,450 physicians have prescribed ARCALYST since launch, versus an estimated 25,000–30,000 physicians seeing recurrent pericarditis patients annually; Q3 penetration was 23% of the 14,000 patients with two or more recurrences.
The estimated total eligible population is 40,000, including 26,000 patients at first recurrence; ~45% of patients who stop treatment later restart.
RESONANCE registry analyses found a 96%–98% lower recurrence risk with rilonacept versus transition to steroids in second-line use; first-recurrence patients showed similar risk reductions.
Pipeline and market opportunity
KPL-387 is in Phase III PASTORALE; Phase II results supported 300 mg SC every four weeks, with response in four days, CRP reduction or normalization in ~1 week, and inflammatory suppression across the monthly interval.
KPL-387 Phase III data are expected in H2 2027; the monthly liquid formulation may support an auto-injector, and management described it as wholly owned and outside the Regeneron profit split.
Market research found >75% of patients and >92% of healthcare professionals preferred KPL-387’s target profile for recurrent pericarditis treatment.
KPL-1161, a potentially quarterly IL-1α/β inhibitor, is expected to enter the clinic later in 2026.
Management emphasized dual IL-1α and IL-1β inhibition, citing their roles in local tissue response and downstream inflammatory amplification in recurrent pericarditis.
Financial outlook and capital allocation
FY2026 revenue guidance is $1.045 billion–$1.050 billion; management cited continued ARCALYST enrollment growth and market penetration as ongoing opportunities.
Higher manufacturing volumes and late-stage KPL-387 and KPL-1161 development were cited as contributors to increased SG&A; management described the business as profitable with a strong cash position.
Capital allocation will prioritize growth in the commercial and clinical pipeline, with a high bar for additional value-creating opportunities.
- ARCALYST growth lifted Q3 sales and guidance as KPL-387 advanced.KNSA
Q3 2026 - Record Q2 revenue and pipeline progress highlight strong growth and future potential.KNSA
Wells Fargo 21st Annual Healthcare Conference - Strong ARCALYST growth, expanding pipeline, and targeted outreach drive future opportunities.KNSA
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 55% to $243.6M, net income $25.4M, and guidance raised to $980–$995M.KNSA
Q2 2026 - Steady ARCALYST growth and advancing abiprubart trials highlight strong momentum and outlook.KNSA
7th Annual Evercore ISI HealthCONx Healthcare Conference - 62% revenue growth in 2025, strong pipeline progress, and significant market opportunity remain.KNSA
TD Cowen 46th Annual Health Care Conference - Q2 ARCALYST revenue up 90% YoY to $103.4M; 2024 guidance raised to $405–$415M.KNSA
Q2 2024 - Q1 2025 ARCALYST revenue jumped 75%, boosting guidance and returning to profitability.KNSA
Q1 2025 - ARCALYST revenue jumped 79% in 2024, with strong 2025 guidance and pipeline progress.KNSA
Q4 2024
)
)
)
)
)
)
)
)